Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC
Status:
Withdrawn
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that the addition of ramucirumab and N-803 will augment the
clinical activity of atezolizumab, and in order to evaluate the exact mechanism of action of
the combination, the investigators propose a comprehensive analysis of paired peripheral
blood samples collected during this study.